Display options
Cite
Ramzy A, Thompson DM, Ward-Hartstonge KA, et al. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell. 2021;28(12):2047-2061.e5doi: 10.1016/j.stem.2021.10.003.
Ramzy, A., Thompson, D. M., Ward-Hartstonge, K. A., Ivison, S., Cook, L., Garcia, R. V., Loyal, J., Kim, P. T. W., Warnock, G. L., Levings, M. K., & Kieffer, T. J. (2021). Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell stem cell, 28(12), 2047-2061.e5. https://doi.org/10.1016/j.stem.2021.10.003
Ramzy, Adam, et al. "Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes." Cell stem cell vol. 28,12 (2021): 2047-2061.e5. doi: https://doi.org/10.1016/j.stem.2021.10.003
Ramzy A, Thompson DM, Ward-Hartstonge KA, Ivison S, Cook L, Garcia RV, Loyal J, Kim PTW, Warnock GL, Levings MK, Kieffer TJ. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell. 2021 Dec 02;28(12):2047-2061.e5. doi: 10.1016/j.stem.2021.10.003. PMID: 34861146.
Copy Download .nbib Format: NLM
Share it on

Cell Stem Cell. 2021 Dec 02;28(12):2047-2061.e5. doi: 10.1016/j.stem.2021.10.003.

Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes.

Cell stem cell

Adam Ramzy, David M Thompson, Kirsten A Ward-Hartstonge, Sabine Ivison, Laura Cook, Rosa V Garcia, Jackson Loyal, Peter T W Kim, Garth L Warnock, Megan K Levings, Timothy J Kieffer

Affiliations

  1. Laboratory of Molecular and Cellular Medicine, Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
  2. Division of Endocrinology, Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
  3. Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; BC Children's Hospital Research Institute (BCCHRI), Vancouver, BC V5Z 4H4, Canada.
  4. Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
  5. Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; BC Children's Hospital Research Institute (BCCHRI), Vancouver, BC V5Z 4H4, Canada; School of Biomedical Engineering, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
  6. Laboratory of Molecular and Cellular Medicine, Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z3, Canada; School of Biomedical Engineering, University of British Columbia, Vancouver, BC V6T 1Z3, Canada. Electronic address: [email protected].

PMID: 34861146 DOI: 10.1016/j.stem.2021.10.003

Abstract

An open-label, first-in-human phase 1/2 study is being conducted to evaluate the safety and efficacy of pancreatic endoderm cells (PECs) implanted in non-immunoprotective macroencapsulation devices for the treatment of type 1 diabetes. We report an analysis on 1 year of data from the first cohort of 15 patients from a single trial site that received subcutaneous implantation of cell products combined with an immunosuppressive regimen. Implants were well tolerated with no teratoma formation or severe graft-related adverse events. After implantation, patients had increased fasting C-peptide levels and increased glucose-responsive C-peptide levels and developed mixed meal-stimulated C-peptide secretion. There were immunosuppression-related transient increases in circulating regulatory T cells, PD1

Copyright © 2021 Elsevier Inc. All rights reserved.

Keywords: C-peptide; cell therapy; diabetes; embryonic stem cells; islet transplantation; pancreatic endoderm cells

Conflict of interest statement

Declaration of interests T.J.K. has received research funding from CRISPR Therapeutics, funding and research contracts from Aspect Biosystems, consulting fees from Sigilon Therapeutics, and research s

Publication Types